-
Chinese Contributions at AASLD 2024: Dr. Yanyan Yu and Dr. Jinghang Xu’s Team Reveal Clinical Features and Prognostic Factors of HBV-Associated Glomer
Study 1: High Proportion of HBsAg-Negative Patients in HBV-GN: A Retrospective Cohort Study HBV-GN, a prevalent secondary glomerular disease in China, has traditionally been associated with positive HBsAg. However, recent…
-
CCHIO 2024丨Dr. Chunfang Hao: Advances in Breast Cancer Precision Treatment—Target Selection and Drug Innovation
Breast cancer remains one of the most significant threats to women’s health. The continuous evolution of treatment strategies reflects the rapid advancement of medical technology. In recent years, precision treatment for breast cancer has become a focal point of research, with accurate target selection and innovative drug development being of paramount importance. At the 2024…
-
CCHIO 2024丨Dr. Man Li: Systematic Breast Cancer Treatment — Precision Medicine Leading the Future
Breast cancer remains a major threat to women’s health, with continuous advancements in treatment strategies being a focal point for the medical community. In China, as the concept of precision medicine gains momentum, systematic breast cancer treatment is gradually moving towards more personalized and precise approaches. At the 2024 Chinese Congress of Holistic Integrative Oncology…
-
CCHIO 2024丨Dr. Nanlin Li: Current Status, Challenges, and Future Directions of Breast Cancer Screening for Chinese Women
Breast cancer remains a major threat to women’s health, and early screening plays a crucial role in reducing both incidence and mortality. However, compared to developed countries in Europe and North America, China still faces numerous challenges in breast cancer screening. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) during the Breast Oncology…
-
CCHIO 2024丨Dr. Yinying Wu: Advances in CLDN18.2-Positive Gastric Cancer Research
At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) held from November 14–17 in Xi’an, Dr. Yinying Wu from The First Affiliated Hospital Xi’an Jiao Tong University delivered a comprehensive lecture titled “Advances in CLDN18.2-Positive Gastric Cancer Research.” The presentation delved into the role of CLDN18.2 protein in gastric cancer, advancements in drug therapies,…
-
CCHIO 2024丨Dr. Yong Zeng: Sharing West China Hospital’s Experience in ERAS for Perioperative Hepatectomy
At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Yong Zeng from West China Hospital Sichuan University presented a keynote lecture titled “Advances and Clinical Practice of Enhanced…
-
CSCO 2024 | NEOPRISM-CRC Study PI Discusses “Reducing Toxicity and Enhancing Efficacy” Strategies for Neoadjuvant Immunotherapy in Locally Advanced
Neoadjuvant therapy for locally advanced colorectal cancer has made significant progress over the past 20 years, but it still faces limitations such as adverse reactions, organ dysfunction, and unsatisfactory control of distant metastasis. In recent years, with the improvement of surgical techniques and further development of tumor molecular typing research, how to further improve local…
-
Chinese Expertise at AASLD 2024: Dr. Qin Ning’s Team Achieves New Breakthroughs in CHB Clinical Cure Strategies
The second study evaluated the efficacy of a triple therapy combining TLR-7 agonist TQ-A3334, PD-L1 antibody TQ-B2450, and NA in virologically suppressed CHB patients. The results demonstrated that the triple…
Connecting Medical Expertise through Media